An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Odevixibat (Primary)
- Indications Intrahepatic cholestasis
- Focus Registrational; Therapeutic Use
- Acronyms PEDFIC 2
- Sponsors Albireo AB
- 22 Oct 2018 Status changed from active, no longer recruiting to recruiting.
- 28 Sep 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 06 Jul 2018 New trial record